FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Immunotherapy topics
Immunotherapy
Therapeutics
Antibodies
Immune Response
Monoclonal
Monoclonal Antibody
Stimulator
Immunostimulator
Compatibility
Histocompatibility
Specificity
Major Histocompatibility Complex
Radiation Therapy
Treatments
Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immunotherapy patents



      
           
This page is updated frequently with new Immunotherapy-related patent applications. Subscribe to the Immunotherapy RSS feed to automatically get the update: related Immunotherapy RSS feeds. RSS updates for this page: Immunotherapy RSS RSS


Date/App# patent app List of recent Immunotherapy-related patents
01/22/15
20150024006
 Allogeneic cellular immunotherapy for opportunistic infection patent thumbnailnew patent Allogeneic cellular immunotherapy for opportunistic infection
A method for stimulating the immune system in immunocompromised patients in order to treat opportunistic infection. The method involves the infusion of intentionally mismatched allogeneic cells.
Immunovative Therapies, Ltd.
01/22/15
20150023993
 Combination therapy using active immunotherapy patent thumbnailnew patent Combination therapy using active immunotherapy
The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (mhc) class-i or class-ii. Preferably the multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof..
Immatics Biotechnologies Gmbh
01/22/15
20150023938
 Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens patent thumbnailnew patent Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
Methods for preparing ex vivo t cell cultures using il-21 compositions for use in adoptive immunotherapy are described. Addition of il-21 to cultures of non-terminally differentiated t cells population, either isolated or present in peripheral blood mononuclear cells are exposed to one or more tumor antigens, and in the presence of il-21 compositions and antigen presenting cells (apcs), the resulting t cell population has an enhanced antigen-specificity, and can be reintroduced into the patient.
Fred Hutchinson Cancer Research Center
01/22/15
20150023910
 Granulysin in immunotherapy patent thumbnailnew patent Granulysin in immunotherapy
Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kd granulysin thereby producing a monocyte-derived dendritic cell.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
01/15/15
20150017137
 Drug resistant immunotherapy for treatment of a cancer patent thumbnailDrug resistant immunotherapy for treatment of a cancer
The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer. The methods also relate to generating a drug-resistant cytotoxic immune cell line and uses thereof in conjunction with cytotoxic drugs.
Emory University
01/15/15
20150017136
 Methods for engineering allogeneic and highly active t cell for immunotherapy patent thumbnailMethods for engineering allogeneic and highly active t cell for immunotherapy
The present invention relates to methods for developing engineered t-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying t-cells by inactivating both genes encoding t-cell receptor and an immune checkpoint gene to unleash the potential of the immune response.
Cellectis
01/08/15
20150010613
 Compositions and methods for cancer immunotherapy patent thumbnailCompositions and methods for cancer immunotherapy
The present invention provides a combination therapy which relies on a small molecule immune stimulator—cyclic-di-nucleotide (cdn)—that activates dcs via a recently discovered cytoplasmic receptor known as sting (stimulator of interferon genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of gm-csf. This combination therapy can provide an ideal synergy of multiple tumor associated antigens, dc recruitment and proliferation, coupled with a potent dc activation stimulus..
Aduro Biotech
01/08/15
20150010587
 Kidney-specific tumor vaccine directed against kidney tumor antigen g-250 patent thumbnailKidney-specific tumor vaccine directed against kidney tumor antigen g-250
This invention provides an anti-cancer immunogenic agent(s) (e.g. Vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a g250 antigenic marker.
The Regents Of The University Of California
12/25/14
20140377761
 Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy patent thumbnailMethods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy
The present invention concerns methods for determining if a dendritic cell belongs to a tolerogenic dendritic cell subset or to an effector dendritic cell subset, and methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory t cell response or towards an effector t cell response, and methods of determining response to immunotherapy.. .
Stallergenes S.a.
12/25/14
20140377299
 Immunotherapy targeting intracellular pathogens patent thumbnailImmunotherapy targeting intracellular pathogens
The present invention relates to the use of immunogenic peptides comprising a t-cell epitope derived from an intracellular pathogen-associated antigen and a redox motif such as c-(x)2-[cst] or [cst]-(x)2-c in the prevention and/or treatment of infection with an intracellular pathogen and in the manufacture of medicaments therefore.. .
Life Sciences Research Partners Vzw
12/25/14
20140377293

Methods for treating newly diagnosed multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone


Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
Celgene Corporation
12/25/14
20140377250

Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency


Compositions including at least one pnp inhibitor or at least one pnp inhibitor in combination with one or more agents identified as endogenous adjuvants useful for enhancing the potency of vaccine and cancer immunotherapies being administered for the prevention or treatment of infectious diseases or cancer. The compositions may be formulated as pharmaceutical dosage forms and components may be assembled as kits.
Nitor Therapeutics
12/25/14
20140377218

Hcv immunotherapy


The invention relates to the use of interleukin-7 (il-7), for treating hepatitis c in a patient infected with hepatitis c virus, wherein said patient has been treated or is being treated with an antiviral agent or a combination of antiviral agents that reduces viral load.. .
Cytheris
12/18/14
20140370099

Artificial antigen presenting cells having a defined and dynamic shape


Compositions and methods comprising asymmetrical artificial antigen presenting cells (aapcs) are disclosed. The non-spherical aapcs more closely mimic endogenous cell-cell interactions and can be used for antigen-specific immunotherapy..
The Johns Hopkins University
12/18/14
20140370086

Sublingual immunotherapy with reduced oral itchiness


Sublingual immunotherapy (slit) with reduced oral itchiness is disclosed. The improved sublingual immunotherapy combines a monotonically increasing dose of allergen, along with a constant dose of mast cell stabilizer, thereby substantially avoiding the oral itchiness and other uncomfortable adverse reactions typically experienced with slit, which can improve patient compliance.
12/18/14
20140370039

Il-12 immunotherapy for cancer


Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems.
University Health Network
12/18/14
20140369940

Anti-alpha synuclein binding molecules


Provided are anti-human α-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human α-synuclein binding molecules which bind to specific n-terminal and c-terminal epitopes on human α-synuclein.
Biogen Idec International Neuroscience Gmbh
12/11/14
20140363470

Pharmaceutical formulations and the use thereof for the treatment of peanut allergy


The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals, such as human mammals, suffering from peanut allergy. The present invention further relates to the use of the present compositions for the therapeutic treatment for desentizing the immune system of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment of a mammal with high predisposition to develop a certain allergy.
12/11/14
20140363446

Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics


This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
12/04/14
20140356930

Immune system enhancing immunotherapy for the treatment of cancer


This application discloses immunoconjugates comprising antibodies against a particular target (such as cancer associated antigen or cancer specific antigen) that are conjugated with an immune enhancer, recruiter or solicitor. Also discloses are compositions and methods of using the inventive immunoconjugates to treat cancer..
12/04/14
20140356398

Adoptive transfer of cd8+ t cell clones derived from central memory cells


The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic t lymphocytes (ctl) preparation in a treatment-effective amount. The method comprises administering as the ctl preparation a preparation consisting essentially of an in vitro expanded primate ctl population, the ctl population enriched prior to expansion for central memory t lymphocytes, and depleted prior to expansion of effector memory t lymphocytes.
12/04/14
20140356372

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor


The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (sit) regimen.
11/27/14
20140349402

Car+ t cells genetically modified to eliminate expression of t-cell receptor and/or hla


The present invention concerns methods and compositions for immunotherapy employing a modified t cell comprising disrupted t cell receptor and/or hla and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf treatment of medical conditions such as cancer, autoimmunity, and infection.
11/27/14
20140348902

Tcl1 peptides for immunotherapy


Provided are tcl1 peptides that bind to mhc i (hla-a2) on tumor cells or other antigen-presenting cells and are recognized by t-cell receptors on t cells. The tcl1 peptides may be therapeutically used to treat a cancer, such as a b cell malignancy, leukemia, or lymphoma.
11/27/14
20140348846

Anti-hla class-ib antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (ivig) useful as therapeutic ivig mimetics and methods of their use


Provided herein are compositions comprising anti-hla-ib antibodies (monoclonal, mixed monoclonal, recombinant, chimeric, humanized or human antibodies) as ivig mimetics and methods for using the same for the prevention, treatment, therapy and/or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-hla-ib antibodies strongly mimic ivig in immunoreactivity to hla class ia (hla-a, hla-b and hla-cw) and ib antigens (hla-e, hla-f and hla-g).
11/27/14
20140348843

Apoe immunotherapy


The present invention provides antibodies that preferentially bind to an apoe(1-272) fragment relative to apoe(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases..
11/27/14
20140348783

Vaccine immunotherapy for immune suppressed patients


A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive t-cells and restoring t-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive t-cells and exposing the naive t-cells to endogenous or exogenous antigens at an appropriate site.
11/27/14
20140348782

Vaccine immunotherapy for immune suppressed patients


A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive t-cells and restoring t-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive t-cells and exposing the naive t-cells to endogenous or exogenous antigens at an appropriate site.
11/27/14
20140348743

Monoclonal antibodies to programmed death 1 (pd-1)


The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
11/20/14
20140341982

Vaccination with immuno-isolated cells producing an immunomodulator


The present invention relates to immuno-protected encapsulated cells producing an immunomodulator, for example gm-csf (granulocyte-macrophage colony stimulating factor). The cells of the invention are particularly well adapted for providing an active adjuvant or immunomodulator, for example in the context of immunisation in humans and animals.
11/20/14
20140341978

Cancer immunotherapy


We formulated multiple tlr agonists into gvax (lethally irradiated tumor cell vaccines engineered to secrete gm-csf). Specifically, gla and r848, tlr4 and tlr7/8 agonists found to be safe in patients, were formulated with gvax (tegvax—for tlr agonists enhanced gvax), and this formulation was effective in producing anti-tumor responses in 3 different preclinical models, including palpable b16.
11/20/14
20140341931

Soluble cd27 (scd27) and the use thereof


Disclosed are methods of diagnosing a subject as having a solid tumor or a predisposition to developing a solid tumor. The methods include detecting or quantitating the amount of scd27 in a serum sample obtained from a subject and comparing that amount of scd27 with a control value indicative of the basal level of scd27 present in the serum of a subject that does not have a solid tumor or a predisposition to developing a solid tumor, wherein a reduction of the amount of scd27 relative to the control value indicates that the subject has the solid tumor or the predisposition to developing the solid tumor.
11/13/14
20140335549

Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays


The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy.
11/06/14
20140328833

Methods for treating cancer using anti-pd-1 antibodies


The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
10/30/14
20140322253

Cyclin a1-targeted t-cell immunotherapy for cancer


Compositions and methods are provided for eliciting antigen-specific t-cell responses against human cyclin a1 (ccna1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (aml) including leukemia stem cells (lsc) and in immunologically privileged testis cells, but not in other normal cell types. Ccna1-derived peptide epitopes that are immunogenic for t-cells including ctl are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells..
10/30/14
20140322183

Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy


The present invention provides compositions and methods for regulating the specificity and activity of t cells. In one embodiment, the invention provides a type of chimeric antigen receptor (car) wherein the car is termed a “kir-car” which is a car design comprising a component of a receptor naturally found on natural killer (nk) cells.
10/23/14
20140314795

Method and compositions for cellular immunotherapy


The present invention provides methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring genetically modified tumor specific cd8+ t cells in the presence of tumor-specific, subset specific genetically modified cd4+ t cells, wherein the cd4+ t cells confer and/or augment a cd8+ t cells ability to sustain anti-tumor reactivity and increase and/or maximize tumor-specific proliferation of the tumor-specific cd8+ t cells of interest. Pharmaceutical formulations produced by the method, and methods of using the same, are also described..
10/16/14
20140308344

Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation


Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient.
10/16/14
20140308305

Yeast-based vaccines as immunotherapy


Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed..
10/16/14
20140308299

Combination immunotherapy for the treatment of cancer


Agonists to icos in combination with a blocking agent to a t cell inhibitory receptor (e.g., ctla-4, pd-1, etc.) are demonstrated herein to be useful for the treatment of tumors.. .
10/09/14
20140302098

Yeast-based vaccines as immunotherapy


Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed..
10/09/14
20140301945

Human anti-sod1 antibodies


Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or sod1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for sod1 are also disclosed.
10/02/14
20140296480

Peptide secreted by lactobacillus plantarum with immunomodulating function


To summarize, the st peptide is considered to promote the process of immunologic ignorance of our gastrointestinal immune system toward the commensal bacteria of our gastrointestinal tract, thus favoring the mechanisms of oral tolerance. Therefore the st peptide could be used in immunotherapy, especially in the context of certain autoimmune diseases and certain inflammatory diseases..
10/02/14
20140294852

Monoclonal antibodies to programmed death 1 (pd-1)


The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
10/02/14
20140294765

Lsr antibodies, and uses thereof for treatment of cancer


This invention relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for lsr molecules, which are suitable drugs for immunotherapy and treatment of specific cancer.. .
09/25/14
20140286974

Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the pfr1 protein of leishmania infantum with specific immunodominant epitopes


The present invention claims an isolated nucleotide sequence characterized by encoding the pfr1 protein of leishmania infantum or a fragment thereof. This pfr1 protein or a fragment thereof comprises at least a selected immunodominant epitope between the following group: seq id no: 1, seq id no: 2, seq id no: 3, seq id no: 4, seq id no: 5, seq id no: 6, seq id no: 7 and seq id no: 8, where the immunodominant epitope is able to induce an antigen-specific t cell cytotoxic immune response in an animal, against the kinetoplastids causing the leishmaniasis disease.
09/25/14
20140286963

Methods and compositions for neural disease immunotherapy


The invention provides antibodies to specific neural proteins and methods of using the same.. .
09/18/14
20140275495

Humanized antibodies that recognize alpha-synuclein


The present application discloses humanized 9e4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of lewy body disease..
09/18/14
20140271836

Manufacture of peanut formulations for oral desensitization


The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies..
09/18/14
20140271721

Peanut formulations and uses thereof


The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy..
09/18/14
20140271692

Novel immunogenic epitopes for immunotherapy


The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
09/18/14
20140271690

Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type


The present disclosure is directed to individual aβ peptide immunogen constructs, peptide compositions comprising these aβ peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these aβ peptide immunogen constructs, with the individual aβ peptide immunogen constructs having the n-terminus of the aβ peptide as the b cell (b) epitopes linked through spacer residue(s) to heterologous t helper cell (th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the n-terminus of the aβ peptide offering protective immune responses to patients at risk for, or with, alzheimer's disease.. .
09/18/14
20140271638

Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas


Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as revlimid® or lenalidomide.
09/18/14
20140271582

Cd123-specific chimeric antigen receptor redirected t cells and methods of their use


A family of chimeric antigen receptors (cars) containing a cd123 specific scfv was developed to target different epitopes on cd123. In some embodiments, such a cd123 chimeric antigen receptor (cd123car) gene includes an anti-cd123 scfv region fused in frame to a modified igg4 hinge region comprising an s228p substitution, an l235e substitution, and optionally an n297q substitution; a costimulatory signaling domain; and a t cell receptor (tcr) zeta chain signaling domain.
09/18/14
20140271477

Monoclonal antibodies to egfr, and uses therefor


The present invention relates to isolated monoclonal anti-egfr antibodies, and to the use of such antibodies and antibody fragments to detect egfr, particularly those expressed by cancer cells. The antibodies are useful in diagnostic as well as therapeutic indications.
09/11/14
20140256648

Hjurp peptides and vaccines including the same


Isolated peptides derived from seq id no: 50 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in cancer immunotherapy are described herein. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, provided they retain the requisite cytotoxic t cell inducibility of the original sequence.
09/11/14
20140255437

Topk peptides and vaccines including the same


The present invention provides isolated epitope peptides derived from topk and immunogenic fragments thereof have an ability to induce cytotoxic t lymphocytes (ctls) and thus are suitable for use in cancer immunotherapy, more particularly as cancer vaccines. The peptides of the present invention encompass both of peptides including a topk-derived amino acid sequence and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted and/or added, provided such modified versions have ctl inducibility.
09/11/14
20140255434

Phl p 5a derivatives having reduced allergeneity and retained t-cell reactivity


The present invention relates to the preparation and use of variants of the group 5 allergen of the pooideae which are characterised by reduced ige reactivity compared with the known wild-type allergens and at the same time by substantially retained reactivity with t lymphocytes. These hypoallergenic allergen variants can be employed for the specific immunotherapy (hyposensitisation) of patients having grass pollen allergy or for the preventative immunotherapy of grass pollen allergies..
09/11/14
20140255433

Pde5 inhibitor compositions and methods for immunotherapy


The invention features methods and compositions featuring a pde5 inhibitor for treating or preventing immunological-mediated disease in a subject.. .
09/11/14
20140255411

Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics


This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
09/11/14
20140255389

Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics


This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against vsig1, ildr1, loc253012, ai216611, c1orf32 or fxyd3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages.
09/11/14
20140255304

Tdp-43 specific binding molecules


Provided are novel tdp-43-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these tdp-43 specific binding molecules.
09/04/14
20140248640

Methods for testing an immune response using cultures of t cells, b cells, dendritic cells and follicular dendritic cells


The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising t cells, b cells and antigen-primed dendritic cells.
09/04/14
20140248297

Predictors of response to immunotherapy


The invention is directed to a method to predict individuals who are likely to respond to immunotherapy by detecting enhanced levels of antibodies in the plasma or serum wherein the antibodies are characteristic of the response or non-response of pretested populations of subjects.. .
09/04/14
20140248283

Monoclonal antibodies against her2 antigens, and uses therefor


The present invention provides and includes monoclonal antibodies (mabs) preferentially selective for her2 antigens, hybridoma lines that secrete these her2 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect her2 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble or secreted form of her2.


Popular terms: [SEARCH]

Immunotherapy topics: Immunotherapy, Therapeutics, Antibodies, Immune Response, Monoclonal, Monoclonal Antibody, Stimulator, Immunostimulator, Compatibility, Histocompatibility, Specificity, Major Histocompatibility Complex, Radiation Therapy, Treatments, Amino Acid

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immunotherapy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunotherapy with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.7744

3560

3 - 0 - 72